CytoDyn Inc.
Datakwaliteit: 83%
CYDY
OTC
Manufacturing
Chemicals
€ 0,29
▲
€ 0,02
(7,04%)
Marktkapitalisatie: 392,21 M
Prijs
€ 0,29
Marktkapitalisatie
392,21 M
Dagbereik
€ 0,28 — € 0,29
52-Weeksbereik
€ 0,20 — € 0,45
Volume
386.514
Openen € 0,29
50D / 200D Gem.
€ 0,25
13,78% above
50D / 200D Gem.
€ 0,28
3,96% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -17,98 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,37
Interest CoverageN/A
Waardering
PE (TTM)
-10,11
Onder sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -10,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -38,79 M |
| ROE | N/A | ROA | -282,83% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -17,98 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,37 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | -31,99 M | Tangible Book Value | -104,29 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -10,11 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -4,58% | ||
| Market Cap | 392,21 M | Enterprise Value | 417,09 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,04 | Revenue / Share | N/A |
| FCF / Share | -0,01 | OCF / Share | -0,01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 46,35% |
| SBC-Adj. FCF | -19,13 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 0,0 | 266.000,0 | — |
| Net Income | 3,75 M | -49,84 M | -79,82 M | -210,82 M | -154,67 M |
| EPS (Diluted) | 0,00 | -0,05 | -0,10 | -0,31 | — |
| Gross Profit | — | — | 213.000,0 | 213.000,0 | — |
| Operating Income | 9,66 M | -18,06 M | -40,58 M | -145,40 M | -104,60 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | 7,24 M | 2,63 M | 27,04 M | 58,43 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 18.000,0 | 29.000,0 | 175.000,0 | 781.000,0 | — |
| Interest Expense | — | 31,78 M | 39,25 M | 65,42 M | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 18,05 M | 11,14 M | 11,29 M | 29,19 M | 132,08 M |
| Total Liabilities | 114,09 M | 127,89 M | 120,79 M | 123,58 M | 153,10 M |
| Shareholders' Equity | -96,04 M | -116,76 M | -109,50 M | -94,40 M | -21,02 M |
| Total Debt | 45,35 M | 45,02 M | 45,73 M | 42,22 M | — |
| Cash & Equivalents | 11,90 M | 3,11 M | 2,54 M | 4,23 M | 33,94 M |
| Current Assets | 17,88 M | 10,82 M | 10,81 M | 10,52 M | 129,58 M |
| Current Liabilities | 70,52 M | 84,18 M | 119,80 M | 123,16 M | 152,55 M |
{"event":"ticker_viewed","properties":{"ticker":"CYDY","listing_kind":"stock","pathname":"/stocks/cydy","exchange":"OTC","country":"US"}}